RESUMO
ABSTRACT Introduction: The diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and, despite all the progress in this field, central nervous system infiltration (CNSi) still occurs at an incidence of 2-10%. The objective of the present study was to evaluate the Central Nervous System International Prognostic Index (CNS-IPI) score in daily practice regarding the reproducibility in a heterogeneous cohort apart from a clinical trial. Methods: Primary DLBCL patients were eligible for this study, between January 2007 and January 2017. All patients were treated with rituximab-based chemotherapy, mostly R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). The CNSi was diagnosed by liquor (positive cytology and/or immunophenotype), computerized tomography, magnetic resonance image and/or fluorodeoxy-glucose-positron emission tomography, requested only in symptomatic patients when the CNSi was clinically suspected. The CNS-IPI was assessed by graphical comparison and calibration. Results: After applying the inclusion/exclusion criteria, 322 patients were available for the analysis. The median follow-up was 60 months and the median age was 58 years. Seven patients experienced CNSi, characterizing an incidence of 2.17% (7/322). Comparing groups of patients with and without CNSi, we observed that the lactate dehydrogenase (LDH), number of extranodal sites, IPI, kidney/adrenal and absence of complete response were statistically different. The CNS-IPI model stratified patients in a three-risk group model as low-, intermediate- and high-risk. In our cohort, using the same stratification, we obtained an equivalent the 2-year rate of CNS relapse of 0.0%, 0.8% and 13.8%, respectively. Conclusion: Our study reinforces the reproducibility of the CNS-IPI, specifically apart from clinical trials, and suggests the CNS-IPI score as a tool to guide therapy.
RESUMO
O vírus sincicial respiratório (RSV) é considerado uma causa importante de morbi-mortalidade em pacientes submetidos ao transplante de células-tronco hematopoéticas (TCTH). Mesmo com o uso da ribavirina inalatória (RI), as taxas de mortalidade são de 30 por cento a 40 por cento . O objetivo deste trabalho foi analisar o perfil dos pacientes infectados pelo RSV e a eficácia do tratamento com RI. Realizou-se uma análise retrospectiva de 59 pacientes submetidos ao TCTH com infecção confirmada pelo RSV (métodos de IFI ou PCR) entre 02/1991 e 02/2008. A RI foi administrada por 12 horas, na dose de 5 g diluída 200 ml de água destilada, por cinco dias. Quinze pacientes apresentaram infecções (TRI) do trato respiratório inferior e 44 pacientes apresentaram infecções (TRS) de vias aéreas superiores. No grupo tratado (n=50), quarenta apresentaram infecções no TRS versus dez TRI; no grupo não tratado, quatro TRS versus cinco TRI. Foram constatados vinte óbitos (33,8 por cento), sendo que 13 desses pacientes (65 por cento dos óbitos) tiveram suas mortes relacionadas ao RSV. Dentre estes, nove pacientes foram a óbito antes da instituição da RI como terapia padrão. A sobrevida global (SG) de todos os pacientes foi de 8,3 meses, sendo 66 por cento para o grupo que utilizou RI versus 11,1 por cento no grupo não tratado(p=0,001). No entanto, a SG foi inferior nos pacientes que apresentaram infecções no TRI (37,5 por cento) quando comparadas às infecções do TRS (65,1 por cento), p=0,007. No modelo de regressão de Cox, a única variável independente encontrada foi o tratamento com RI (p=0,001).
Respiratory syncytial virus (RSV) causes significant mortality in patients submitted to SCT. Despite the use of ribavirin aerosols (RA), mortality rates are still between 30 and 40 percent in many centers. The objective of this study was to analyze the clinical course and outcome of 59 patients who developed RSV infections after SCT in a single institution. In this retrospective analysis, the diagnosis of RSV infection was confirmed in 59 patients submitted to HSCT. RA was administrated during 12 hours at a dose of 5g diluted in 200 mL of distillated water, for 5 days. Fifteen patients presented with upper respiratory tract (URT) infection and 44 patients presented with lower respiratory tract (LRT) infection. In the group of patients who received RA (n=50), 40 had URT infections and 10 had LRT infections. In patients who did not receive RA, 3 had URT infections and 6 had LRT infections. Twenty patients died (33.8 percent) with the main cause of death of 13 patients being RSV infection (all these patients required mechanical ventilation). Nine patients died before RA therapy became standard treatment for RSV (before 1992). The overall survival of patients treated with RA was 66 percent. However, the overall survival was lower in patients who had LRT infections (37.5 percent) compared with those who had URT infections (67.5 percent - p=0.007). In the multivariate analysis, only the use of RA affected overall survival (p=0.001).